Vorolanib drug interaction study in healthy volunteers
This study checks how the experimental cancer drug vorolanib interacts with other medicines when taken together. It is for healthy people to help find the right dose and safety information before it is tested in patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy adult aged 18 or older
- You weigh at least 50 kg (110 lbs) if male, or 45 kg (99 lbs) if female
- Your body mass index (BMI) is between 19 and 26
- You have no significant chronic illnesses or long-term health conditions
- You are not taking any prescription or over-the-counter medications, herbal remedies, or supplements for 2 weeks before and during the study
- You can avoid alcohol, grapefruit juice, and excessive caffeine during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how befotertinib, an experimental cancer drug, interacts with other drugs in healthy people. It helps make sure the drug is safe and works well when taken with other medicines.
This trial tests a targeted therapy pill, vorolanib, for people with advanced kidney cancer that has clear cell features and has gotten worse after initial treatment. It may offer a new option when standard second-line treatments are not working.
This study looks at how the body handles the study drug vorolanib (taken as a tablet) when your liver is impaired. It might help doctors understand the right dose for people with liver problems, and it may also benefit those who are newly diagnosed or exploring treatment options.
This study tests how a new medicine (buagafuran) interacts with another medicine (voriconazole) in healthy volunteers. The goal is to understand how the two drugs affect each other in the body, which can help guide safer use in the future.
This study checks if a new oral drug, MDR-001, interacts safely with two common medicines (rifampin and itraconazole) when taken together. It's for healthy volunteers, and the results will help guide dosing for future patients.
This trial tests a targeted therapy pill called Vorolanib for people with advanced non-small cell lung cancer who have already tried at least two other treatments. It aims to see if the drug can help shrink or control the cancer.
Hear when a new DDI (Drug-Drug Interaction) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.